Lap, Remco (2021) Nanocarrier drug-delivery systems for temozolomide in the treatment of glioblastoma multiforme. Bachelor's Thesis, Life Science and Technology.
|
Text
bLST_2021_LAPRP.pdf Download (843kB) | Preview |
|
Text
toestemming.pdf Restricted to Registered users only Download (161kB) |
Abstract
Glioblastoma multiforme (GBM) is an aggressive brain cancer which is very hard to treat. The brain is a delicate tissue protected externally by the skull and internally by the blood brain barrier (BBB). Current standard treatment combines tissue resection, radiation therapy and administration of the chemotherapeutic agent temozolomide (TMZ). The effectivity of this treatment is limited, the non-specificity of TMZ administration gives rise to many side-effects and GBM-patient survival rates are particularly low. Nanocarrier drug-delivery systems offer perspective for the future effectivity of GBM treatment by TMZ delivery across the BBB to GBM tissue. This paper assesses the most extensively studied and promising nanocarrier systems, with the aim of designing a drug delivery system for the co-delivery of TMZ and a chemo-sensitizing drug, suited for transport to the brain, in order to improve the effectivity and efficiency of the treatment of GBM. An extensive literature survey was conducted to TMZ-carrying nanoparticles (NPs), after which the NPs ability of the dual-loading of TMZ and the chemo-sensitizer curcumin (CUR) were assessed. The resulting, proposed nanocarrier system for GBM treatment is a reduction sensitive, pegylated, TMZ/CUR dual-loaded nanostructured lipid carrier (NLC), able to cross the BBB by targeting transferrin receptors (TfRs) using T7-peptides.
Item Type: | Thesis (Bachelor's Thesis) |
---|---|
Supervisor name: | Zuhorn, I.S. and Rijn, P. van |
Degree programme: | Life Science and Technology |
Thesis type: | Bachelor's Thesis |
Language: | English |
Date Deposited: | 21 May 2021 08:59 |
Last Modified: | 21 May 2021 08:59 |
URI: | https://fse.studenttheses.ub.rug.nl/id/eprint/24433 |
Actions (login required)
View Item |